Brian Barnett

1.7k total citations
34 papers, 1.2k citations indexed

About

Brian Barnett is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Brian Barnett has authored 34 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 12 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Brian Barnett's work include CAR-T cell therapy research (11 papers), Immune Cell Function and Interaction (6 papers) and Immunotherapy and Immune Responses (6 papers). Brian Barnett is often cited by papers focused on CAR-T cell therapy research (11 papers), Immune Cell Function and Interaction (6 papers) and Immunotherapy and Immune Responses (6 papers). Brian Barnett collaborates with scholars based in United States, United Kingdom and Sweden. Brian Barnett's co-authors include Weiping Zou, Tyler J. Curiel, Joanne T. Douglas, Ilona Kryczek, Pui Cheng, Linhua Zou, Vincent F. LaRussa, Peter Mottram, Shuang Wei and Odile David and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Brian Barnett

31 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian Barnett United States 15 565 542 383 358 97 34 1.2k
Deanna M. Grote United States 13 698 1.2× 546 1.0× 212 0.6× 365 1.0× 86 0.9× 23 1.4k
Sarah L. Buchan United Kingdom 18 829 1.5× 434 0.8× 392 1.0× 102 0.3× 71 0.7× 26 1.1k
Franziska Blaeschke Germany 18 449 0.8× 832 1.5× 658 1.7× 288 0.8× 99 1.0× 33 1.4k
Jan Martínek United States 7 492 0.9× 397 0.7× 244 0.6× 117 0.3× 84 0.9× 14 924
Dimitrios L. Wagner Germany 13 483 0.9× 1.2k 2.2× 904 2.4× 532 1.5× 96 1.0× 26 1.8k
Laura K. Aguilar United States 22 537 1.0× 791 1.5× 444 1.2× 512 1.4× 23 0.2× 45 1.5k
HE Heslop United States 18 592 1.0× 460 0.8× 313 0.8× 314 0.9× 485 5.0× 32 1.4k
Guang Huan Tu United States 9 520 0.9× 599 1.1× 541 1.4× 278 0.8× 17 0.2× 11 1.2k
Haruko Tashiro Japan 13 536 0.9× 1.3k 2.4× 477 1.2× 449 1.3× 166 1.7× 57 1.6k
L. Bronz Switzerland 9 538 1.0× 417 0.8× 213 0.6× 171 0.5× 89 0.9× 21 1.3k

Countries citing papers authored by Brian Barnett

Since Specialization
Citations

This map shows the geographic impact of Brian Barnett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Barnett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Barnett more than expected).

Fields of papers citing papers by Brian Barnett

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Barnett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Barnett. The network helps show where Brian Barnett may publish in the future.

Co-authorship network of co-authors of Brian Barnett

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Barnett. A scholar is included among the top collaborators of Brian Barnett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Barnett. Brian Barnett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barnett, Brian, Nicholas Sharp, Takeo Fujii, et al.. (2025). Efficiency of Fulvestrant Monotherapy After CDK4/6 Inhibitor Exposure: Is This a Viable Choice?. Cancers. 17(5). 884–884.
2.
3.
Barnett, Brian, Sonya G. Gordon, Ashley B. Saunders, et al.. (2023). A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect on cardiac function of low-dose rapamycin in 17 healthy client-owned dogs. Frontiers in Veterinary Science. 10. 1168711–1168711. 10 indexed citations
4.
Creevy, Kate E., et al.. (2023). Development and validation of a novel instrument to capture companion dog mortality data: the Dog Aging Project End of Life Survey. Journal of the American Veterinary Medical Association. 261(9). 1326–1336. 4 indexed citations
5.
McClelland, Robyn L., et al.. (2022). Development and evaluation of a survey instrument to assess veterinary medical record suitability for multi-center research studies. Frontiers in Veterinary Science. 9. 941036–941036.
6.
7.
Gallagher, Christopher, Tripthi Kamath, Anthony Masaquel, et al.. (2016). Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer. Breast Cancer Research and Treatment. 157(1). 145–156. 16 indexed citations
8.
Yardley, Denise A., Ian E. Krop, Patricia LoRusso, et al.. (2015). Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents. The Cancer Journal. 21(5). 357–364. 27 indexed citations
9.
Gallagher, Christopher, Anthony Masaquel, Tripthi Kamath, et al.. (2014). Relapse impact on overall survival in trastuzumab-treated women with HER2+ early-stage breast cancer.. Journal of Clinical Oncology. 32(15_suppl). e11601–e11601. 1 indexed citations
10.
Elliott, Robert L., et al.. (2011). Human Leukocyte Antigen G Expression in Breast Cancer: Role in Immunosuppression. Cancer Biotherapy and Radiopharmaceuticals. 26(2). 153–157. 40 indexed citations
11.
Barnett, Brian, Jens Rüter, Ilona Kryczek, et al.. (2008). Regulatory T cells. Advances in experimental medicine and biology. 622. 255–260. 3 indexed citations
12.
Barnett, Brian, et al.. (2008). Immune tolerance induction for the eradication of inhibitors in patients with hemophilia A. Expert Opinion on Biological Therapy. 8(12). 1885–1896. 3 indexed citations
13.
Barnett, Brian, Rebecca Kruse‐Jarres, & Cindy Leissinger. (2008). Current management of acquired factor VIII inhibitors. Current Opinion in Hematology. 15(5). 451–455. 18 indexed citations
14.
Barnett, Brian, Jens Rüter, Pui Cheng, et al.. (2006). Phase II trial of Ontak to deplete regulatory T cells in treatment-refractory stage III/IV ovarian cancer. Cancer Research. 66. 1148–1148. 1 indexed citations
15.
Curiel, Tyler J., Brian Barnett, Ilona Kryczek, Pui Cheng, & Weiping Zou. (2006). Regulatory T cells in ovarian cancer: biology and therapeutic potential. 6. 20. 9 indexed citations
16.
Barnett, Brian, Ilona Kryczek, Pui Cheng, Weiping Zou, & Tyler J. Curiel. (2005). Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential. American Journal of Reproductive Immunology. 54(6). 369–377. 181 indexed citations
17.
Hemminki, Akseli, Anna Kanerva, Eric J. Kremer, et al.. (2003). A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Molecular Therapy. 7(2). 163–173. 83 indexed citations
18.
Zinn, Kurt R., Brian Barnett, L A Sumerel, et al.. (2002). The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. European Journal of Cancer. 38(14). 1917–1926. 118 indexed citations
19.
Barnett, Brian, et al.. (2002). Targeted adenoviral vectors. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1575(1-3). 1–14. 134 indexed citations
20.
Barnett, Brian, Bryan Tillman, David T. Curiel, & Joanne T. Douglas. (2002). Dual Targeting of Adenoviral Vectors at the Levels of Transduction and Transcription Enhances the Specificity of Gene Expression in Cancer Cells. Molecular Therapy. 6(3). 377–385. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deanna M. Grote Breakdown of academic impact, for papers by Sarah L. Buchan Breakdown of academic impact, for papers by Franziska Blaeschke Breakdown of academic impact, for papers by Jan Martínek Breakdown of academic impact, for papers by Dimitrios L. Wagner Breakdown of academic impact, for papers by Laura K. Aguilar Breakdown of academic impact, for papers by HE Heslop Breakdown of academic impact, for papers by Guang Huan Tu Breakdown of academic impact, for papers by Haruko Tashiro Breakdown of academic impact, for papers by L. Bronz
Rankless by CCL
2026